Gabri Labs, a pharmaceutical technologies company, has announced its plans to build a 10,000ft2 facility to manufacture medical devices.
In this regard, the firm has signed on with Dubai Science Park to build a medical devices facility with an investment of $4.9m (AED18m).
Go deeper with GlobalData
The new facility will allow the pharmaceutical brand to create an initial volume of 12 million units per year with additional expansions planned by next year.
The medical devices will be distributed to markets across the Middle East and North Africa (MENA) region.
A privately held pharmaceutical company based in Dover, Delaware, US, Gabri Labs has production facilities across Europe and the Middle East.
See Also:
The brand has presence in therapeutic ENT and dermatology spheres. It develops over-the-counter products and medical devices.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe new Dubai facility will support the production of multiple lines and a diverse product portfolio.
This portfolio includes ENT brand, OTOMAR, and dermatological solutions line, Curadem.
Dubai Science Park managing director Marwan Abdulaziz Janahi said: “Our leadership’s focused efforts to advance the manufacturing sector and boost innovation under Operation 300bn are directly enhancing Dubai’s healthcare landscape.
“Dubai Science Park strives to facilitate the expansion of international firms like Gabri Labs by continually providing them access to robust infrastructure, communication with key regulatory bodies and a collaborative ecosystem that eases business set-up and growth.”
Gabri Labs managing director Elio Gebrayel said, “We are thrilled to enter a new chapter of our story in Dubai and the wider MENA region with the construction of our brand-new facility in the emirate.
“Dubai Science Park’s dynamic business environment and robust infrastructure have been essential in facilitating our seamless setup, allowing us to easily access MENA’s diverse markets while participating in a vibrant community of researchers, scientists, pharmacists and more.
“Our new facility will allow us to cater to more patients across the region and continue innovating and leading the therapeutic ENT and dermatology sectors.”
————————————————————————————————————–
Image: The new Dubai facility will support the production of multiple lines and a diverse product portfolio. Credit: PublicDomainPictures from Pixabay.
